Associated Papers
Genomic landscape of metastatic breast cancers in young adults: a liquid biopsy analysis of women aged 20-40 years.
Diab E et al.
Breast (edinburgh, Scotland), 2026
ESR1 mutation in Endocrine treatment naive Endometrial Cancer: Prevalence, Characteristics and Prognostic Implications, results from the UTOLA phase II GINECO trial.
Blanc-Durand F et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2026
Comparative Analysis of a Dual DNA-RNA Panel and a DNA-Only Panel for Sarcoma: Real-World Data From a Nationwide Genomic Database.
Nakata E et al.
Cancer Science, 2026
Assessing endocrine resistance: monitoring circulating ESR1 mutations in Irosustat-treated ER positive breast cancer.
Page K et al.
Breast Cancer Research and Treatment, 2025
Concurrent genomic assessment of circulating tumour cells and ctDNA to guide therapy in metastatic breast cancer.
Allsopp RC et al.
Bmc Cancer, 2025
ESR1 analysis of liquid biopsy in breast cancer, one-year routine experience of an Italian clinical referral center.
Maloberti T et al.
The Journal of Liquid Biopsy, 2025
ESR1 ctDNA testing: literature review and comparison of assays for ESR1 mutation detection in advanced hormone receptor-positive breast cancer.
Yarunin A et al.
Expert Review of Molecular Diagnostics, 2025
Incidence of ESR1 gene mutations among patients with endometrioid endometrial cancer.
Jang M et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society, 2025
Diagnostic utility of ESR1 mutation detection in liquid biopsy of metastatic breast cancer patients.
Sandbothe M et al.
Virchows Archiv : an International Journal of Pathology, 2025
Retrospective comparison between breast cancer tissue- and blood-based next-generation sequencing results in detection of PIK3CA, AKT1, and PTEN alterations.
Chaki M et al.
Breast Cancer Research : Bcr, 2025
Detection of ESR1 Mutations in Tissue and Liquid Biopsy with Novel Next-Generation Sequencing and Digital Droplet PCR Assays: Insights from Multi-Center Real Life Data of Almost 6000 Patients.
Borkar S et al.
Cancers, 2025
Cell-free tumor DNA analysis in advanced or metastatic breast cancer patients: mutation frequencies, testing intention, and clinical impact.
Huebner H et al.
Precision Clinical Medicine, 2025
Development and validation of a multi-marker liquid bead array assay for the simultaneous detection of PIK3CA and ESR1 hotspot mutations in single circulating tumor cells (CTCs).
Stergiopoulou D et al.
Heliyon, 2024
Whole-Exome Sequencing Reveals Novel Candidate Driver Mutations and Potential Druggable Mutations in Patients with High-Risk Neuroblastoma.
Nokchan N et al.
Journal of Personalized Medicine, 2024
Estrogen-Receptor Loss and ESR1 Mutation in Estrogen-Receptor-Positive Metastatic Breast Cancer and the Effect on Overall Survival.
Westenend PJ et al.
Cancers, 2024
A phase I dose escalation and expansion trial of the next-generation oral SERD camizestrant in women with ER-positive, HER2-negative advanced breast cancer: SERENA-1 monotherapy results.
Hamilton E et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology, 2024
Liver tropism of ER mutant breast cancer is characterized by unique molecular changes and immune infiltration.
Wu Y et al.
Breast Cancer Research and Treatment, 2024
Identifying prognostic biomarkers for palbociclib add-on therapy in fulvestrant-resistant breast cancer using cell-free DNA sequencing.
Takeshita T et al.
Esmo Open, 2024
ESR1 F404 Mutations and Acquired Resistance to Fulvestrant in ESR1-Mutant Breast Cancer.
Kingston B et al.
Cancer Discovery, 2024
Somatic estrogen receptor α mutations that induce dimerization promote receptor activity and breast cancer proliferation.
Irani S et al.
The Journal of Clinical Investigation, 2024
Next-Generation Sequencing in Breast Cancer Patients: Real-World Data for Precision Medicine.
Lee H et al.
Cancer Research and Treatment, 2024
Open-label, phase II, multicenter study of lasofoxifene plus abemaciclib for treating women with metastatic ER+/HER2- breast cancer and an ESR1 mutation after disease progression on prior therapies: ELAINE 2.
Damodaran S et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology, 2023
Lasofoxifene versus fulvestrant for ER+/HER2- metastatic breast cancer with an ESR1 mutation: results from the randomized, phase II ELAINE 1 trial.
Goetz MP et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology, 2023
Circulating tumor DNA landscape and prognostic impact of acquired resistance to targeted therapies in cancer patients: a national center for precision medicine (PRISM) study.
Bayle A et al.
Molecular Cancer, 2023
ESR1 Gene Mutations and Liquid Biopsy in ER-Positive Breast Cancers: A Small Step Forward, a Giant Leap for Personalization of Endocrine Therapy?
Betz M et al.
Cancers, 2023
Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients.
Pascual J et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2023
Concordance between cancer gene alterations in tumor and circulating tumor DNA correlates with poor survival in a real-world precision-medicine population.
Rosenberg S et al.
Molecular Oncology, 2023
Standing in the canine precision medicine knowledge gap: Improving annotation of canine cancer genomic biomarkers through systematic comparative analysis of human cancer mutations in COSMIC.
Sakthikumar S et al.
Veterinary and Comparative Oncology, 2023
Potential value of ctDNA monitoring in metastatic HR + /HER2 - breast cancer: longitudinal ctDNA analysis in the phase Ib MONALEESASIA trial.
Chiu J et al.
Bmc Medicine, 2023
Efficacy of Olaparib in Treatment-Refractory, Metastatic Breast Cancer with Uncommon Somatic BRCA Mutations Detected in Circulating Tumor DNA.
Yoon JK et al.
Cancer Research and Treatment, 2023
Genomics of Breast Cancer Brain Metastases: A Meta-Analysis and Therapeutic Implications.
Nguyen TT et al.
Cancers, 2023
Efficacy and exploratory biomarker analysis of entinostat plus exemestane in advanced or recurrent breast cancer: phase II randomized controlled trial.
Iwata H et al.
Japanese Journal of Clinical Oncology, 2023
ESR1 activating mutations: From structure to clinical application.
Grinshpun A et al.
Biochimica Et Biophysica Acta. Reviews on Cancer, 2023
Validation of liquid biopsy for ESR1-mutation analysis in hormone-sensitive breast cancer: a pooled meta-analysis.
Najim O et al.
Frontiers in Oncology, 2023
Molecular characterization of ESR1 variants in breast cancer.
Heeke AL et al.
Breast Cancer Research and Treatment, 2022
Integrative genomic and transcriptomic analyses illuminate the ontology of HER2-low breast carcinomas.
Berrino E et al.
Genome Medicine, 2022
Detection of ESR1 Mutations in Primary Tumors and Plasma Cell-Free DNA in High-Grade Serous Ovarian Carcinoma Patients.
Stergiopoulou D et al.
Cancers, 2022
Predictors of fulvestrant long-term benefit in hormone receptor-positive/HER2 negative advanced breast cancer.
Torrisi R et al.
Scientific Reports, 2022
AMEERA-1 phase 1/2 study of amcenestrant, SAR439859, in postmenopausal women with ER-positive/HER2-negative advanced breast cancer.
Bardia A et al.
Nature Communications, 2022
Molecular landscape of TP53 mutations in breast cancer and their utility for predicting the response to HER-targeted therapy in HER2 amplification-positive and HER2 mutation-positive amplification-negative patients.
Liu B et al.
Cancer Medicine, 2022
Diagnostic Validation of a Comprehensive Targeted Panel for Broad Mutational and Biomarker Analysis in Solid Tumors.
Froyen G et al.
Cancers, 2022